Randomized phase II trial of parsatuzumab (Anti-EGFL7) or placebo in combination with FOLFOX and bevacizumab for first-line metastatic colorectal cancer

Oncologist

Volumn 22, Issue 4, 2017, Pages

  García Carbonero, Rocío ^a   Van Cutsem, Eric ^b   Rivera, Fernando ^c   Jassem, Jacek ^d   Gore, Ira ^e   Tebbutt, Niall ^f   Braiteh, Fadi ^g   Argiles, Guillem ^h   Wainberg, Zev A ⁱ   Funke, Roel ^j   Anderson, Maria ^j   McCall, Bruce ^j   Stroh, Mark ^j   Wakshull, Eric ^j   Hegde, Priti ^j   Ye, Weilan ^j   Chen, Daniel ^j   Chang, Ilsung ^j   Rhee, Ina ^j   Hurwitz, Herbert ^k  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^d MEDICAL UNIVERSITY OF GDANSK   (Poland)

^e Birmingham Hematology and Oncology Associates   (United States)

^f AUSTIN HEALTH   (Australia)

^g Department of Hematology Oncology   (United States)

^h HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j GENENTECH INC   (United States)

^k DUKE UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; MESSENGER RNA; OXALIPLATIN; PARSATUZUMAB; PLACEBO; TRANSCRIPTION FACTOR ZEB1; VASCULOTROPIN; ANTIIDIOTYPIC ANTIBODY; ANTINEOPLASTIC AGENT; EGFL7 PROTEIN, HUMAN; ENDOTHELIAL CELL GROWTH FACTOR; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADULT; AGED; ARTERIAL THROMBOEMBOLISM; ARTICLE; BLEEDING; CANCER STAGING; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ELECTROCORTICOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HYPERTENSION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM; WOUND HEALING; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METASTASIS; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; ENDOTHELIAL GROWTH FACTORS; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS;

EID: 85017530406     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2016-0133     Document Type: Article

References (19)

1. Schmidt M, Paes K, DeMaziere A et al. Egfl7 regulates the collective migration of endothelial cells by restricting their spatial distribution. Development 2007; 134: 2913-2923.
2. Parker LH, Schmidt M, Jin SW et al. The endothelial-cell-derived secreted factor EGFL7 regulates vascular tube formation. Nature 2004; 428: 754-758.
3. Xu D, Perez RE, Ekekezie, II et al. Epidermal growth factor-like domain 7 protects endothelial cells from hyperoxia-induced cell death. Am J Physiol Lung Cell Mol Physiol 2008; 294: L17-23.
4. Soncin F, Mattot V, Lionneton F et al. Ve-statin, an endothelial repressor of smooth muscle cell migration. EMBO 2003; 22: 5700-5711.
5. Fitch MJ, Campagnolo L, Kuhnert F et al. Egfl7, a novel epidermal growth factor-domain gene expressed in endothelial cells. Dev Dyn 2004; 230: 316-324.
6. Yeung S, Smyczek T, Cheng J et al. Inhibiting vascular morphogenesis in tumors: Egfl7 as a novel therapeutic target. Cancer Res 2011; 71: 3295-3295.
7. Johnson L, Huseni M, Smyczek T et al. Anti-egfl7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy. J Clin Invest 2013; 123: 3997-4009.
8. Naumovski L, Gordon M, Munster P et al. A phase 1b dose-escalation study of the safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the humanized monoclonal antibody (humab) anti-EGFL7 (MEGF0444A) in combination with bevacizumab with or without paclitaxel in patients with advanced solid tumors. J Clin Oncol 2011; 29 (suppl 20): 2514.
9. Hochster HS, Hart LL, Ramanathan RK et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as firstline treatment of metastatic colorectal cancer: Results of the tree study. J Clin Oncol 2008; 26: 3523-3529.
10. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase 3 study. J Clin Oncol 2008; 26: 2013-2019.
11. Xin Y, Gordon M, Jin D et al. Population pharmacokinetic (PK) analysis supports fixed dosing for the humanized monoclonal antibody (humab) anti-EGFL7 (megf0444a) administered intravenously in patients with advanced solid tumors. J Clin Oncol 2011; 29 (May 20 Suppl): 2586.
12. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
13. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the eastern cooperative oncology group study e3200. J Clin Oncol 2007; 25: 1539-1544.
14. Bennouna J, Sastre J, Arnold D et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ml18147): A randomised phase 3 trial. Lancet Oncol 2013; 14: 29-37.
15. Campagnolo L, Leahy A, Chitnis S et al. Egfl7 is a chemoattractant for endothelial cells and is upregulated in angiogenesis and arterial injury. Am J Pathol 2005; 167: 275-284.
16. Inai T, Mancuso M, Hashizume H et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004; 165: 35-52.
17. Mancuso MR, Davis R, Norberg SM et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006; 116: 2610-2621.
18. Vosseler S, Mirancea N, Bohlen P et al. Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res 2005; 65: 1294-1305.
19. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005; 15: 102-111.